Cotadutide significantly reduces blood sugar and weight in diabetics with CKD: Study
UK: A recent study in the journal Diabetes, Obesity and Metabolism has found that cotadutide is an effective treatment option in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The treatment was shown to significantly improve postprandial blood sugar control and reduce bodyweight versus placebo.
"Reductions in urinary albumin-to-creatinine ratios suggest potential benefits of cotadutide on kidney function. further evaluation in larger, longer-term clinical trials may be warranted," Victoria E. R. Parker, AstraZeneca, Cambridge, UK, and colleagues wrote in their study.
Cotadutide (MEDI0382) is a balanced GLP-1 and glucagon receptor dual agonist, with an approx ratio of 5:1 GLP-1 to glucagon activity. Dr. Parker and colleagues conducted the study with an objective to assess the safety, efficacy and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease in a phase 2a study.
The study included patients with body mass index 25-45 kg/m2, estimated glomerular filtration rate 30-59 ml/min/1.73 m2 and type 2 diabetes [glycated haemoglobin 6.5-10.5% (48-91 mmol/mol)] controlled with insulin and/or oral therapy combination. They were randomized in the ratio of 1:1 to once-daily subcutaneous cotadutide (50-300 μg) or placebo for 32 days. Plasma glucose concentration assessed using a mixed-meal tolerance test was the primary endpoint.
Salient findings of the study include:
- Participants receiving cotadutide (n = 21) had significant reductions in the mixed-meal tolerance test area under the glucose concentration-time curve (–26.71% vs. +3.68%), more time in target glucose range on continuous glucose monitoring (+14.79% vs. –21.23%) and significant reductions in absolute bodyweight (–3.41 kg vs. –0.13 kg) versus placebo (n = 20).
- In patients with baseline micro- or macroalbuminuria (n = 18), urinary albumin-to-creatinine ratios decreased by 51% at day 32 with cotadutide versus placebo.
- No statistically significant difference was observed in mean change in estimated glomerular filtration rate between treatments.
- Mild/moderate adverse events occurred in 71.4% of participants receiving cotadutide and 35.0% receiving placebo.
Cotadutide improved glycaemic control and weight loss in patients with type 2 diabetes and CKD, and also shows the potential to reduce albuminuria.
"Based on the growing evidence of the shared pathogenetic mechanisms underlying type 2 diabetes, NAFLD/non-alcoholic steatohepatitis and CKD, and the improved glycaemic control, enhanced insulin sensitivity, reduction in bodyweight and improved lipid and hepatic biomarkers in obese patients with type 2 diabetes, cotadutide may be a potentially beneficial therapy in patients with CKD and type 2 diabetes," wrote the authors.
Reference:
The study titled, "Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease," was published in the journal Diabetes, Obesity and Metabolism.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.